Bodnar P M, Ian'zhon' V, Prystupiuk O M, Lopushenko N I
Lik Sprava. 1993 Oct-Dec(10-12):102-4.
Carbonic fibrous enterosorbent "Vuglesorb" used as a part of complex anti-diabetic treatment contributes to normalization of metabolism, promotes liquidation of ketoacidosis and principal morbid manifestations. Alongside with this, glycaemia and fructosamine blood level come to the norm. Marked anti-atherogenic effect was also observed. The drug is recommended for the treatment of patients with diabetes mellitus.
碳酸纤维肠吸附剂“Vuglesorb”作为综合抗糖尿病治疗的一部分使用，有助于新陈代谢正常化，促进酮症酸中毒的消除和主要病态表现的改善。与此同时，血糖和血液中果糖胺水平恢复正常。还观察到明显的抗动脉粥样硬化作用。该药物推荐用于治疗糖尿病患者。
